ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission Guidance
January 14 2008 - 6:30AM
PR Newswire (US)
ANX-530 Demonstrates Statistically Significant Reduction in
Injection Site Reactions SAN DIEGO, Jan. 14 /PRNewswire-FirstCall/
-- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced safety
results from its marketing-enabling bioequivalence clinical study
of ANX-530 (vinorelbine emulsion). ANX-530 demonstrated a
statistically significant reduction in injection site reactions
when compared to Navelbine(R) (p
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024
